Eikon Therapeutics (EIKN) grants 67,044 stock options to executive Thorner

Rhea-AI Filing Summary

Eikon Therapeutics, Inc. reported that executive Benjamin Bruno Thorner received a grant of stock options covering 67,044 shares of the company’s stock. The options have an exercise price of $0.00 per share and represent a new award rather than an open-market purchase.

According to the vesting terms, one forty-eighth of the option shares will vest on each monthly anniversary of the vesting start date over 48 months, as long as Thorner continues to provide service to the company. This structure ties the award to multi-year retention and ongoing employment.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Thorner Benjamin Bruno

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	67,044	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 67,044 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thorner Benjamin Bruno

(Last) (First) (Middle)

C/O EIKON THERAPEUTICS, INC.

230 HARRIET TUBMAN WAY

(Street)

MILLBRAE CA 94030

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Eikon Therapeutics, Inc. [ EIKN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.88	03/02/2026		A		67,044		(1)	03/01/2036	Common Stock	67,044	$0.00	67,044	D

Explanation of Responses:

1. 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.

Remarks:

General Counsel and Chief Business Officer

	/s/ Benjamin Thorner	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did EIKN report for Benjamin Bruno Thorner?

Eikon Therapeutics reported that executive Benjamin Bruno Thorner received a grant of stock options for 67,044 shares. This is a compensatory award rather than a market trade, reflecting equity-based incentives linked to his ongoing service with the company.

How many Eikon Therapeutics (EIKN) shares are covered by the new option grant?

The new stock option grant to Benjamin Bruno Thorner covers 67,044 shares of Eikon Therapeutics common stock. All 67,044 option shares are reported as directly owned following the transaction, subject to the vesting schedule described in the filing footnote.

What is the exercise price of Benjamin Bruno Thorner’s EIKN stock options?

The stock options granted to Benjamin Bruno Thorner have an exercise price of $0.00 per share. This indicates the options were issued as a compensatory award, with value primarily driven by vesting and the company’s future stock performance rather than a cash outlay by the executive.

How do the EIKN options granted to Benjamin Bruno Thorner vest over time?

The options vest monthly over four years. Specifically, 1/48th of the 67,044 underlying shares vests on each monthly anniversary of the vesting start date, provided Thorner continues to serve Eikon Therapeutics through each respective vesting date.

Is the EIKN Form 4 transaction a buy or sell of existing shares?

The Form 4 transaction is an acquisition of derivative securities through a grant, not a buy or sell of existing shares on the open market. It reflects a stock option award as part of compensation rather than a discretionary trading decision by Benjamin Bruno Thorner.

What ownership type is reported for Benjamin Bruno Thorner’s new EIKN options?

The filing reports the 67,044 option shares as directly owned by Benjamin Bruno Thorner. There is no indication of indirect ownership through a trust, partnership, or other entity, and no footnote disclaimer of beneficial ownership or voting and investment authority.